Risk of gynecomastia and breast cancer associated with the use of 5-alpha reductase inhibitors for benign prostatic hyperplasia

BACKGROUND: Clinical trial results suggest that 5-alpha reductase inhibitors (5ARIs) for the treatment of benign prostatic hyperplasia (BPH) may increase the risk of gynecomastia and male breast cancer, but epidemiological studies have been limited. PATIENTS AND METHODS: We conducted a cohort study...

Descripción completa

Detalles Bibliográficos
Autores principales: Hagberg, Katrina Wilcox, Divan, Hozefa A, Fang, Shona C, Nickel, J Curtis, Jick, Susan S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312705/
https://www.ncbi.nlm.nih.gov/pubmed/28228662
http://dx.doi.org/10.2147/CLEP.S124674

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312705/
https://www.ncbi.nlm.nih.gov/pubmed/28228662
http://dx.doi.org/10.2147/CLEP.S124674

Ejemplares similares